Cargando…
Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa
BACKGROUND: This post hoc subanalysis examined outcomes in adult patients with Morquio A (mucopolysaccharidosis IVA) who received enzyme replacement therapy (ERT) with elosulfase alfa over a 120-weeks period. Patients ≥18 years of age evaluated in an open-label, long-term extension study of elosulfa...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442692/ https://www.ncbi.nlm.nih.gov/pubmed/28535791 http://dx.doi.org/10.1186/s13023-017-0634-0 |
_version_ | 1783238446151630848 |
---|---|
author | Hughes, D. Giugliani, R. Guffon, N. Jones, S. A. Mengel, K. E. Parini, R. Matousek, R. Hawley, S. M. Quartel, A. |
author_facet | Hughes, D. Giugliani, R. Guffon, N. Jones, S. A. Mengel, K. E. Parini, R. Matousek, R. Hawley, S. M. Quartel, A. |
author_sort | Hughes, D. |
collection | PubMed |
description | BACKGROUND: This post hoc subanalysis examined outcomes in adult patients with Morquio A (mucopolysaccharidosis IVA) who received enzyme replacement therapy (ERT) with elosulfase alfa over a 120-weeks period. Patients ≥18 years of age evaluated in an open-label, long-term extension study of elosulfase alfa (modified per protocol [MPP], n = 32; intent-to-treat [ITT], n = 37; MOR-005; NCT01415427) were compared with the ≥18-year-old untreated population with 2-years follow-up from a Morquio A natural history study (n = 10; MorCAP; NCT00787995). The MOR-005 MPP population excluded patients who underwent orthopedic surgical procedures or were noncompliant with study protocol (defined as missing ≥20% of ERT infusions). No MorCAP patients underwent orthopedic surgical procedures during the relevant time period. Endurance was assessed by the 6-min walk test (6MWT) and 3-min stair climb test (3MSCT). Activities of daily living (ADLs) were assessed by the MPS Health Assessment Questionnaire (MPS HAQ). RESULTS: Least squares (LS) mean (SE) 6MWT distances increased by 34.9 (11.7) m (MPP) and 30.5 (10.8) m (ITT) by week 120; LS mean (SE) change in 3MSCT at week 120 was 6.7 (1.8) stairs/min (MPP) and 5.9 (1.7) stairs/min (ITT). MorCAP patients showed no improvement in 6MWT distance or 3MSCT over a similar period of time. Pulmonary function measures remained unchanged in both MOR-005 and MorCAP adults. All MPS HAQ domain scores improved in MOR-005 adults, whereas MorCAP adults had unchanged caregiver assistance and mobility outcomes and worsened self-care outcomes. CONCLUSIONS: Long-term ERT in adult patients with Morquio A was associated with increased endurance and improvement in performance of ADLs. TRIAL REGISTRATION: Trial Registration NCT01415427. Name of registry: Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome). Registered 8 August 2011, retrospectively registered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13023-017-0634-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5442692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54426922017-05-25 Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa Hughes, D. Giugliani, R. Guffon, N. Jones, S. A. Mengel, K. E. Parini, R. Matousek, R. Hawley, S. M. Quartel, A. Orphanet J Rare Dis Research BACKGROUND: This post hoc subanalysis examined outcomes in adult patients with Morquio A (mucopolysaccharidosis IVA) who received enzyme replacement therapy (ERT) with elosulfase alfa over a 120-weeks period. Patients ≥18 years of age evaluated in an open-label, long-term extension study of elosulfase alfa (modified per protocol [MPP], n = 32; intent-to-treat [ITT], n = 37; MOR-005; NCT01415427) were compared with the ≥18-year-old untreated population with 2-years follow-up from a Morquio A natural history study (n = 10; MorCAP; NCT00787995). The MOR-005 MPP population excluded patients who underwent orthopedic surgical procedures or were noncompliant with study protocol (defined as missing ≥20% of ERT infusions). No MorCAP patients underwent orthopedic surgical procedures during the relevant time period. Endurance was assessed by the 6-min walk test (6MWT) and 3-min stair climb test (3MSCT). Activities of daily living (ADLs) were assessed by the MPS Health Assessment Questionnaire (MPS HAQ). RESULTS: Least squares (LS) mean (SE) 6MWT distances increased by 34.9 (11.7) m (MPP) and 30.5 (10.8) m (ITT) by week 120; LS mean (SE) change in 3MSCT at week 120 was 6.7 (1.8) stairs/min (MPP) and 5.9 (1.7) stairs/min (ITT). MorCAP patients showed no improvement in 6MWT distance or 3MSCT over a similar period of time. Pulmonary function measures remained unchanged in both MOR-005 and MorCAP adults. All MPS HAQ domain scores improved in MOR-005 adults, whereas MorCAP adults had unchanged caregiver assistance and mobility outcomes and worsened self-care outcomes. CONCLUSIONS: Long-term ERT in adult patients with Morquio A was associated with increased endurance and improvement in performance of ADLs. TRIAL REGISTRATION: Trial Registration NCT01415427. Name of registry: Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome). Registered 8 August 2011, retrospectively registered. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13023-017-0634-0) contains supplementary material, which is available to authorized users. BioMed Central 2017-05-23 /pmc/articles/PMC5442692/ /pubmed/28535791 http://dx.doi.org/10.1186/s13023-017-0634-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Hughes, D. Giugliani, R. Guffon, N. Jones, S. A. Mengel, K. E. Parini, R. Matousek, R. Hawley, S. M. Quartel, A. Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa |
title | Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa |
title_full | Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa |
title_fullStr | Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa |
title_full_unstemmed | Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa |
title_short | Clinical outcomes in a subpopulation of adults with Morquio A syndrome: results from a long-term extension study of elosulfase alfa |
title_sort | clinical outcomes in a subpopulation of adults with morquio a syndrome: results from a long-term extension study of elosulfase alfa |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442692/ https://www.ncbi.nlm.nih.gov/pubmed/28535791 http://dx.doi.org/10.1186/s13023-017-0634-0 |
work_keys_str_mv | AT hughesd clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa AT giuglianir clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa AT guffonn clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa AT jonessa clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa AT mengelke clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa AT parinir clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa AT matousekr clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa AT hawleysm clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa AT quartela clinicaloutcomesinasubpopulationofadultswithmorquioasyndromeresultsfromalongtermextensionstudyofelosulfasealfa |